T cell CRISPR screen
Research type
Research Study
Full title
Establishment and use of CRISPR based phenotypic screens in primary human T cells to identify novel immuno-oncology drug targets
IRAS ID
271859
Contact name
Stuart Farrow
Contact email
Sponsor organisation
CRT
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Although immuno-oncology therapies, and in particular T cell-targeted therapies, are having a huge impact on the lives of cancer patients, many patients do not respond to existing immuno-oncology drugs. It would be advantageous, therefore, to identify novel genes that control T cell activity. Such genes may represent new drug targets that could be exploited to activate anti-tumour immunity.
CRISPR technology allows precise editing of the genome of cells to knockout individual genes and can be used in phenotypic screens to identify genes of interest. Indeed, CRISPR screening has been previously used successfully in phenotypic T cell screens. By establishing T cell CRISPR screening, we aim to identify novel drug targets which could be exploited via either small molecule or antibody-based therapeutics to increase the immune response to tumours.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
20/WM/0012
Date of REC Opinion
14 Feb 2020
REC opinion
Further Information Favourable Opinion